Abstract
Many countries across the globe utilized medical and non-medical facemasks as non-pharmaceutical intervention for reducing the transmission and infectivity of coronavirus disease-2019 (COVID-19). Although, scientific evidence supporting facemasks’ efficacy is lacking, adverse physiological, psychological and health effects are established. Is has been hypothesized that facemasks have compromised safety and efficacy profile and should be avoided from use. The current article comprehensively summarizes scientific evidences with respect to wearing facemasks in the COVID-19 era, providing prosper information for public health and decisions making.
Keywords:Physiology, Psychology, Health, SARS-CoV-2, Safety, Efficacy
Introduction
Facemasks are part of non-pharmaceutical interventions providing some breathing barrier to the mouth and nose that have been utilized for reducing the transmission of respiratory pathogens[1]. Facemasks can be medical and non-medical, where two typ
Abstract
Many countries across the globe utilized medical and non-medical facemasks as non-pharmaceutical intervention for reducing the transmission and infectivity of coronavirus disease-2019 (COVID-19). Although, scientific evidence supporting facemasks’ efficacy is lacking, adverse physiological, psychological and health effects are established. Is has been hypothesized that facemasks have compromised safety and efficacy profile and should be avoided from use. The current article comprehensively summarizes scientific evidences with respect to wearing facemasks in the COVID-19 era, providing prosper information for public health and decisions making.
Keywords:Physiology, Psychology, Health, SARS-CoV-2, Safety, Efficacy
Introduction
Facemasks are part of non-pharmaceutical interventions providing some breathing barrier to the mouth and nose that have been utilized for reducing the transmission of respiratory pathogens[1]. Facemasks can be medical and non-medical, where two typ
Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results
On track to fuel the pipeline with =4 new product candidates in 2021
Strong cash position of €64 million year-end to execute ambitious growth plan
14 commercial products expected by 2024
Conference call and
Liège, Belgium - 9 March 2021 -
Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 December 2020, recent achievements, and an outlook for 2021.
Stijn Van Rompay, Chief Executive Officer of Hyloris, commented:
I am extremely proud of the significant progress we have made across all areas of our business, which has set a strong foundation to execute our ambitious growth plan. We are committed to changing the lives of patients by applying our knowhow and innovative technol
The science driving BLS CPR recommendations ems1.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ems1.com Daily Mail and Mail on Sunday newspapers.